Preferential Hyperacuity Perimetry: Perspectives of Self-Monitoring of Neovascular Activity in Patients with Age-Related Macular Degeneration
DOI:
https://doi.org/10.17140/OOJ-1-e002Keywords:
neovascularization, prospectivelyAbstract
The socio-economic burden of age-related macular degeneration (AMD) has strongly
increased in public health importance due to the aging of the general population, and in clinics
because of the world-wide use of anti-vascular endothelial growth factor (anti-VEGF) drugs
in patients with neovascular AMD (NV-AMD).1-5 In all health care services of the developed
countries, a large portion of NV-AMD burden is related to the growing human resources employed to carry out those frequent monitoring visits required to verify the necessity of antiVEGF repetition. In view of recent findings in earlier diagnosis of AMD-related choroidal neovascularization (CNV) by means of the self-monitoring with preferential hyperacuity perimetry
(PHP) device,6-8 possibilities and limitations of this innovative self-monitoring approach, whose
rationale exploits the human “Vernier acuity” visual function,9,10 should be investigate to verify
its ability in detecting the need for anti-VEGF retreatments among patients with NV-AMD, and
to prospectively reduce the costs for the clinical governance of this sight-threatening disease.
References
Day S, Acquah K, Lee PP, Mruthyunjaya P, Sloan FA. Medicare costs for neovascular age-related macular degeneration, 1994- 2007. Am J Ophthalmol. 2011; 152(6): 1014-1020. doi: 10.1016/j.ajo.2011.05.008
Qualls LG, Hammill BG, Wang F, et al. Costs of newly diagnosed neovascular age-related macular degeneration among medicare beneficiaries, 2004-2008. Retina. 2013; 33(4): 854-861. doi: 10.1097/IAE.0b013e31826f065e
Haller JA. Current anti-vascular endothelial growth factor dosing regimens: benefits and burden. Ophthalmology. 2013; 120(5 Suppl): S3-S7. doi: 10.1016/j.ophtha.2013.01.057
Jonas JB. Global prevalence of age-related macular degeneration. Lancet Glob Health. 2014; 2(2): e65-e66. doi: 10.1016/S2214- 109X(13)70163-3
Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014; 2(2): e106-e116. doi: 10.1016/S2214-109X(13)70145-1
Chew EY, Clemons TE, Bressler SB, et al. AREDS2-HOME Study Research Group. Randomized trial of a home monitoring sys-tem for early detection of choroidal neovascularization home monitoring of the Eye (HOME) study. Ophthalmology. 2014; 121(2): 535-544. doi: 10.1016/j.ophtha.2013.10.027
Faes L, Bodmer NS, Bachmann LM, Thiel MA, Schmid MK. Diagnostic accuracy of the Amsler grid and the preferential hy-peracuity perimetry in the screening of patients with age-related macular degeneration: systematic review and meta-analysis. Eye (Lond). 2014; 28(7): 788-796. doi: 10.1038/eye.2014.104
Han DP. The ForeSeeHome device and the HOME study: a milestone in the self-detection of neovascular age-related macular degeneration. JAMA Ophthalmol. 2014; 132(10): 1167-1168. doi: 10.1001/jamaophthalmol.2014.1405
Westheimer G. Editorial: Visual acuity and hyperacuity. Invest Ophthalmol. 1975; 14(8): 570-572.
Alster Y, Bressler NM, Bressler SB, et al. Preferential Hyperacuity Perimetry Research Group. Preferential Hyperacuity Perim-eter (PreView PHP) for detecting choroidal neovascularization study. Ophthalmology. 2005; 112(10): 1758-1765. doi: 10.1016/j. ophtha.2005.06.008
Bourne RR, Stevens GA, White RA, et al. Vision Loss Expert Group. Causes of vision loss worldwide, 1990-2010: a systematic analysis. Lancet Glob Health. 2013; 1(6): e339-e349. doi: 10.1016/S2214-109X(13)70113-X
Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Oph-thalmol. 1984; 102(11): 1640-1642. doi: 10.1001/archopht.1984.01040031330019
Klein R, Peto T, Bird A, Vannewkirk MR. The epidemiology of age-related macular degeneration. Am J Ophthalmol. 2004; 137(3): 486-495. doi: 10.1016/j.ajo.2003.11.069
Bressler NM, Doan QV, Varma R, et al. Estimated cases of legal blindness and visual impairment avoided using ranibizumab for choroidal neovascularization: non-hispanic white population in the United States with age-related macular degeneration. Arch Ophthalmol. 2011; 129(6): 709-717. doi: 10.1001/archophthalmol.2011.140
Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012; 153(2): 209-213. doi: 10.1016/j.ajo.2011.10.016
Keenan TD, Kelly SP, Sallam A, Mohamed Q, Tufail A, Johnston RL. Incidence and baseline clinical characteristics of treated neovascular age-related macular degeneration in a well-defined region of the UK. Br J Ophthalmol. 2013; 97(9): 1168-1172. doi: 10.1136/bjophthalmol-2013-303233
Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study: a non-interventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol. 2013; 91(6): 540-546. doi: 10.1111/j.1755-3768.2012.02493.x
Rakic JM, Leys A, Brié H, et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthal-mol. 2013; 7: 1849-1858. doi: 10.2147/OPTH.S49385
Finger RP, Guymer RH, Gillies MC, Keeffe JE. The impact of anti-vascular endothelial growth factor treatment on quality of life in neovascular age-related macular degeneration. Ophthalmology. 2014; 121(6): 1246-1251. doi: 10.1016/j.ophtha.2013.12.032
Han DP. Age-related macular degeneration, anti-VEGF therapy, and ophthalmic imaging: is there a best practice? JAMA Oph-thalmol. 2013; 131(9): 1124-1126. doi: 10.1001/jamaophthalmol.2013.432
Tschuor P, Pilly B, Venugopal D, Gale RP. Optimising assessment intervals improves visual outcomes in ranibizumab-treated age-related neovascular degeneration: using the stability phase as a benchmark. Graefes Arch Clin Exp Ophthalmol. 2013; 251(10): 2327-2330. doi: 10.1007/s00417-013-2332-5
Das R, Shi Y, Silvestri G, Chakravarthy U. Distortion maps from preferential hyperacuity perimetry are helpful in monitoring functional response to Lucentis therapy. Retina. 2009; 29(7): 1013-1018. doi: 10.1097/IAE.0b013e3181a91dbf
Querques G, Berboucha E, Leveziel N, Pece A, Souied EH. Preferential hyperacuity perimeter in assessing responsiveness to ranibizumab therapy for exudative age-related macular degeneration. Br J Ophthalmol. 2011; 95(7): 986-991. doi: 10.1136/ bjo.2010.190942
Querques G, Querques L, Rafaeli O, Canoui-Poitrine F, Bandello F, Souied EH. Preferential hyperacuity perimeter as a function-al tool for monitoring exudative age-related macular degeneration in patients treated by intravitreal ranibizumab. Invest Ophthalmol Vis Sci. 2011; 52(9): 7012-7018. doi: 10.1167/iovs.11-7517
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in The Ophthalmology (TOOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.
